CTOs on the Move

Axm Pharma

www.axmpharma.com

 
AXM Pharma, Inc. is a global pharmaceutical company engaged in the production, marketing and distribution of pharmaceutical products in China. The Company produces, markets and distributes medicines in various dosages and forms in areas of medicinal
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.axmpharma.com
  • 7251 W Lake Mead Blvd Ste 300
    Las Vegas, NV USA 89128
  • Phone: 702.562.4155

Executives

Name Title Contact Details

Similar Companies

Immuno Vaccine

Immuno Vaccine is a Halifax, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Athira

At Athira, we aim to restore neuronal health for those suffering from neurological diseases, including Alzheimer`s, so that patients can regain their memories, lives, and family relationships. We are a motivated, impassioned team committed to making a positive impact on human health.

Centric Health Resources

Centric Health Resources is a Chesterfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Healthpoint Biotherapeutics

Healthpoint Biotherapeutics is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KemPharm

KemPharm is a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, approved drugs. Developing and encouraging a unique creativity, leveraged throughout the process of scientific discovery is the foundation of our corporate culture. At KemPharm we employ our Ligand Activated Therapy (LAT™) platform technology to create prodrugs that are new molecules which can improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety. We create new prodrugs by chemically attaching one or more molecules, or ligands, to an FDA-approved parent drug. When combined with the parent drug, our ligands create prodrugs designed to have improved drug attributes while maintaining efficacy equivalent to the parent drug. Once administered, targeted human metabolic processes, such as those in the GI tract, separate the ligand from the prodrug and release the parent drug, which can then exert its therapeutic effect. KemPharm has employed its LAT™ prodrug platform to create a diverse pipeline of prodrug therapeutics that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.